ChengDu Sheng Nuo Biotec (688117.SH): Approval of the application for listing of the raw material drug Vapenapeptide.
Shengnuo Biotechnology (688117.SH) announced that its wholly-owned subsidiary, Chengdu Shengnuo Biopharmaceutical Co., Ltd., recently...
Chengdu Shengnuo Biotech (688117.SH) announced that its wholly-owned subsidiary, Chengdu Shengnuo Biotech Pharmaceutical Co., Ltd., recently received the "Chemical Active Pharmaceutical Ingredients Market Approval Notice" from the National Medical Products Administration (hereinafter referred to as the "NMPA") for the active pharmaceutical ingredient of semaglutide.
Semaglutide is a PEGylated analog of liraglutide that combines and activates the GLP-1 receptor in the body as a GLP-1 receptor agonist. It has similar physiological effects to native human GLP-1, enhancing insulin secretion and lowering blood sugar levels in a glucose-dependent manner, thus treating type 2 diabetes and obesity.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
